CFM
CTXR icon

Catalyst Funds Management’s Citius Pharmaceuticals CTXR Stock Holding History

Catalyst Funds Management’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,088
Closed -$13.6K – 554
2024
Q3 		$13.6K Hold
1,088
– – ﹤0.01% 1142
2024
Q2 		$15.9K Buy
+1,088
New +$19.5K ﹤0.01% 760

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

Catalyst Funds Management's CTXR Position: Q4 2024 in Review

Catalyst Funds Management sold out of Citius Pharmaceuticals (CTXR) in Q4 2024, closing a stake of 1,088 shares — an estimated $13.6K sold.

Catalyst Funds Management first reported a position in CTXR in Q2 2024 and held it in 2 quarters. The position peaked at $15.9K in Q2 2024. 30 funds tracked by Wall St. Rank hold CTXR as of Q4 2024.

  • Catalyst Funds Management reported no remaining Citius Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 1,088 Citius Pharmaceuticals shares in Q4 2024, an estimated $13.6K.
  • Catalyst Funds Management first reported a position in Citius Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Citius Pharmaceuticals position peaked at $15.9K in Q2 2024.
  • 30 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.